MorphoSys AG
XETRA:MOR
Intrinsic Value
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. [ Read More ]
The intrinsic value of one MOR stock under the Base Case scenario is 27.56 EUR. Compared to the current market price of 67.7 EUR, MorphoSys AG is Overvalued by 59%.
Valuation Backtest
MorphoSys AG
Run backtest to discover the historical profit from buying and selling MOR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
MorphoSys AG
Current Assets | 814m |
Cash & Short-Term Investments | 682.8m |
Receivables | 38.9m |
Other Current Assets | 92.4m |
Non-Current Assets | 1.2B |
Long-Term Investments | 3.6m |
PP&E | 15m |
Intangibles | 1.2B |
Other Non-Current Assets | 7.3m |
Current Liabilities | 264.3m |
Accounts Payable | 109.8m |
Other Current Liabilities | 154.5m |
Non-Current Liabilities | 1.7B |
Long-Term Debt | 252.8m |
Other Non-Current Liabilities | 1.5B |
Earnings Waterfall
MorphoSys AG
Revenue
|
238.3m
EUR
|
Cost of Revenue
|
-51m
EUR
|
Gross Profit
|
187.3m
EUR
|
Operating Expenses
|
-420.2m
EUR
|
Operating Income
|
-232.9m
EUR
|
Other Expenses
|
43.2m
EUR
|
Net Income
|
-189.7m
EUR
|
Free Cash Flow Analysis
MorphoSys AG
What is Free Cash Flow?
MOR Profitability Score
Profitability Due Diligence
MorphoSys AG's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
Score
MorphoSys AG's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
MOR Solvency Score
Solvency Due Diligence
MorphoSys AG's solvency score is 31/100. The higher the solvency score, the more solvent the company is.
Score
MorphoSys AG's solvency score is 31/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MOR Price Targets Summary
MorphoSys AG
According to Wall Street analysts, the average 1-year price target for MOR is 57.12 EUR with a low forecast of 17.17 EUR and a high forecast of 71.4 EUR.
Shareholder Return
MOR Price
MorphoSys AG
Average Annual Return | -26.38% |
Standard Deviation of Annual Returns | 50.4% |
Max Drawdown | -91% |
Market Capitalization | 2.5B EUR |
Shares Outstanding | 37 594 501 |
Percentage of Shares Shorted |
N/A
|
MOR News
Last Important Events
MorphoSys AG
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
MorphoSys AG
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. The company is headquartered in Planegg, Bayern and currently employs 648 full-time employees. The firm develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The firm's operating segments include Proprietary Development and Partnered Discovery. In the Proprietary Development segment, it develops therapeutic antibodies and peptides in the area of inflammatory disease and oncology. In the Partnered Discovery segment, the Company applies technologies for the research, development and optimization of therapeutic antibodies as drug candidates. The firm develops new treatments for patients suffering from serious diseases. Its technologies include HuCAL, which is a collection fully human antibodies and a system for their optimization; Ylanthia, which is an antibody library in Fab format, and Slonomics, an automated technology for gene synthesis and modification for the generation of gene libraries in a controlled process.
Contact
IPO
Employees
Officers
The intrinsic value of one MOR stock under the Base Case scenario is 27.56 EUR.
Compared to the current market price of 67.7 EUR, MorphoSys AG is Overvalued by 59%.